Join

Compare · BTTX vs NVS

BTTX vs NVS

Side-by-side comparison of Better Therapeutics Inc. (BTTX) and Novartis AG (NVS): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both BTTX and NVS operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
  • NVS is the larger of the two at $292.08B, about 3428.4x BTTX ($85.2M).
  • NVS has hit the wire 1 time in the past 4 weeks while BTTX has been quiet.
  • NVS has more recent analyst coverage (25 ratings vs 2 for BTTX).
MetricBTTXNVS
Company
Better Therapeutics Inc.
Novartis AG
Price
$0.05+28.53%
$152.93-0.66%
Market cap
$85.2M
$292.08B
1M return
-
+2.10%
1Y return
-
+29.48%
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Exchange
NASDAQ
NYSE
IPO
2021
News (4w)
0
1
Recent ratings
2
25
BTTX

Better Therapeutics Inc.

Better Therapeutics, Inc. develops prescription digital therapeutics that delivers behavioral therapy, and creates feedback mechanisms using remotely monitored and patient-generated data. Its products include Nutritional Cognitive Behavioral Therapy (Nutritional CBT), behavioral therapy for patients with type 2 diabetes and other cardiometabolic diseases. It also manufactures therapeutic medicines, such as BT—001, BT—002, BT—003, BT—004, and BT—005 for cardiometabolic diseases. The company was incorporated in 2015 and is based in San Francisco, California.

NVS

Novartis AG

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers. It also provides ophthalmology, neuroscience, immunology, hepatology and dermatology, respiratory, established, and cardiovascular, renal and metabolism medicine products. The Sandoz segment provides active ingredients and finished dosage forms of small molecule pharmaceuticals to third parties across a range of therapeutic areas, as well as finished dosage form anti-infectives. It also provides active pharmaceutical ingredients and intermediates primarily antibiotics; protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services. Novartis AG has a license and collaboration agreement with Alnylam Pharmaceuticals to develop, manufacture, and commercialize inclisiran; an agreement with CureVac to manufacture COVID-19 vaccine candidate CVnCoV; a collaboration with Artios Pharma Limited to create next generation DDR cancer therapies; and a clinical collaboration with Kura Oncology, Inc. to evaluate the combination of Tipifarnib and Alpelisib in patients with head and neck squamous cell carcinoma. The company was incorporated in 1996 and is headquartered in Basel, Switzerland.